Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

North American Cancer Screening Market (2018-2023): Expected to Grow at a CAGR of 11.14% to Reach $16.36 Billion by 2023 - ResearchAndMarkets.com

Research and Markets
Posted on: 15 Nov 18
The "North America Cancer Screening Market (2018-2023)" report has been added to ResearchAndMarkets.com's offering. The market is forecasted to grow at a compound annual growth rate (CAGR) of 11.14% resulting in an annual revenue of USD 16.36 billion during the forecast period 2018-2023.

North America is leading the cancer screening market. The region is technologically equipped and being a developed economy it is efficiently catering to the rising incidence of cancer cases.

Companies are focusing on research & development (R&D) and entering into collaborations with the government to expand regional access. The rising incidence of cancer cases has led to a growing need among people to seek early cure and diagnosis. Technological advancements being adopted at a rapid pace to combat the rapid spread of cancer are the key growth factors for the market.

The North America cancer screening market is a mature market for cancer screening and is forecasted to grow at a growth rate of 8.3%. But regulatory hindrances in the form of policies and norms which has the potential to impact the growth of the market.

By end-users, the market is segmented into hospitals, laboratories and independent physicians and clinics. The Laboratory segment will witness a progressive growth during the forecast period 2018-2023 while the hospital segment will account for the maximum revenue of USD 11.18 billion during the forecast period.

By screening type, the market is segmented into laboratory, genetic, imaging, biopsy and endoscopy tests. Genetic and biopsy will be the leading segments during the forecast period 2018-2023.

By application type, the market can be segmented into lung, breast, melanoma, kidney and colorectal cancer types. Colorectal, kidney, melanoma and breast cancer will occupy a larger share of the market during the forecast period 2018-2023.

By countries, the market is divided into the United States of America (U.S.A.), Canada and others (the rest of North America).

Key Players Profiled
  • GE Healthcare
  • Siemens Healthcare GmbH
  • Hologic Inc.
  • Thermo Fisher Scientific
  • Roche Diagnostics

Key Topics Covered

Chapter 1: Executive Summary

Chapter 2: North America Cancer Screening Market - Market Overview

Chapter 3: The USA Cancer Screening Market

Chapter 4: Canada Smart Manufacturing Industry 4.0 Market

Chapter 5: Others (The Rest of North America) Smart Manufacturing Industry 4.0 Market

Chapter 6: Competitive Landscape

Chapter 7: Conclusion

For more information about this report visit https://www.researchandmarkets.com/research/gbb4fx/north_american?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20181115005864/en/

Business Wire
www.businesswire.com

Last updated on: 15/11/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.